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Melanoma can be considered an emerging chronic disease that may considerably affect patients’ lives. The authors
systematically reviewed the available literature on health-related quality of life (HRQOL) and melanoma. Of reviews and
the selected studies, reference lists were hand-searched. The quality of the eligible studies was appraised based on
14 previously published criteria. Of the 158 abstracts, 44 articles were appraised, resulting in 13 selected studies
written in English (published between 2001 and 2008). Most studies assessed patients from specialised centres with
varying, but relatively advanced, disease stages. The most commonly used instruments were the SF-36 and EORTC
QLQ-C30. Recently, a melanoma-speciﬁc HRQOL questionnaire [FACT-Melanoma (FACT-M)] was introduced for
clinical trial purposes. It showed that approximately one-third of melanoma patients experienced considerable levels of
distress, mostly at the time of diagnosis and following treatment. Systemic therapies affected HRQOL negatively in the
short term, but to a lesser extent in the long term. Health status and patients’ psychological characteristics are
associated with higher levels of HRQOL impairment. The authors found that the impact of melanoma on patients’
HRQOL is comparable to that of other cancers. Accurately assessing HRQOL impairment in melanoma patients is
pivotal, as it may affect disease management, including therapy and additional counselling, future preventive behaviour
and perhaps even prognosis.
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introduction
The incidence of cutaneous melanoma has increased
dramatically in the western world in the last few decades (4%
for women and 5% for men, annually) [1]. Despite this rise in
incidence, the mortality rate seems to be levelling off due to
earlier diagnosis [2, 3]. Approximately 70% of melanoma
patients have a Breslow thickness of <1.5 mm, with a 5-year
survival rate of 95%. When lymph nodes are involved, the
survival rate drops to 20–40% [1]. Melanoma affects relatively
young and middle-aged people. Patients with melanoma are
more at risk of developing a new primary melanoma (1.2–
8.2%), and their ﬁrst-degree relatives have a twofold higher risk
of developing melanoma [4]. Despite tremendous efforts,
melanoma treatment has not changed substantially; in most
cases it comprises surgery with or without (sentinel) lymph
node resection. A small group of patients with metastasised
disease receive chemotherapy and/or interferon therapy (often
in clinical trial settings).
About 80% of patients will survive melanoma [1, 3] but
remain at risk for disease progression for many years, for
which there is no successful therapy. Therefore, melanoma can
be considered a chronic, life-threatening disease. Additionally,
patients are aware that UV exposure is an important risk
factor for the development of melanoma, which may affect
their lifestyles as well as their social and professional
activities [5].
Altogether, these observations indicate that melanoma may
have a considerable impact on patients’ lives, including their
health-related quality of life (HRQOL), which the World
Health Organization (WHO) deﬁnes as ‘an individual’s
perception of their position in life in the context of the culture
and value system in which they live and in relation to their
goals, expectations, standards and concerns. This broad
ranging concept is in a complex way affected by the person’s
physical health, psychological state, level of independence,
social relationships, personal beliefs and their relationship to
salient features of their environment. Because in 75% of
patients local surgical excision is an adequate therapy,
HRQOL impairment is predominantly determined by
psychological aspects and, to a lesser extent, by (long-term)
therapy-induced events, as is often observed in other cancers.
The psychosocial issues facing patients with an early stage,
highly curable disease such as melanoma differ from other
types of cancer with profound loco-regional effects or distant
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follow-up surveillance to be worthwhile, they also indicated
that little attention had been paid to their well-being during
surveillance [6].
The objective of this review is to evaluate, summarise and
discuss the available literature concerning HRQOL in patients
with cutaneous melanoma.
methods
Systematic searches were conducted in PubMed, MEDLINE and the
Cochrane Library with the assistance of a medical librarian. The search
algorithm of MeSH-used terms was the following: (cutaneous OR skin)
AND melanoma AND (quality of life OR life) AND (health status OR
health status indicators OR survival analysis OR health-related OR health)
NOT ‘non-melanoma’. Restrictions were not placed on publication dates or
language. Several inclusion and exclusion criteria were used (Figure 1). The
quality of the eligible studies was assessed using criteria for assessing the
methodological quality of studies in HRQOL published previously
(Table 2) [7]. In brief, these criteria focus on the methodological aspects of
HRQOL studies, e.g. whether inclusion and exclusion criteria are well
formulated, whether responders and non-responders are reported and
whether the socio-demographics of the responders are known and the score
range is between 0 and 14. The criteria are quite strict; if a certain criterion
is not explicitly mentioned, the default is 0.
results
included studies
Of the 158 abstracts extracted from PubMed, 114 were
excluded primarily because they did not focus on HRQOL; 44
full articles were reviewed, but only 13 were eligible for this
review (Figure 1). The articles were all in English and published
between 2001 and 2008.
quality of included studies
The included studies varied in quality according to the quality
criteria used (Table 1) [7]. The scores of the eligible studies
ranged between 8 and 12 out of a maximum of 14 (67% and
86%, respectively) (Table 3).
study design and population
Of the 13 studies that assessed HRQOL in melanoma patients,
seven were cohort studies, ﬁve were clinical trials and one was
a cross-sectional population-based study. Three studies
investigated the effects of therapy such as surgery, interferon or
vaccination on patients’ HRQOL. Of the 10 prospective studies,
eight had a study duration of £4 months. Only two studies
followed patients for >2 years after melanoma diagnosis. Six
studies were conducted in the USA, of which three included
Inclusion criteria title/abstract: 
Melanoma 
Cutaneous or Skin 
(HR)QOL assessment 
Any date 
157
Abstracts  
Exclusion  criteria title/abstract: 
Language other than English 
Primary/secondary prevention
of melanoma  
Treatment of melanoma 
Etiology of melanoma
(n=113) 
MEDLINE
Articles included for data-extraction 
13 articles 
N=158 
Exclude duplications
N=1 
Exclusion criteria full text: 
Topics other than (HR)QOL
(29) 
Reviews (2) 
The Cochrane
Library 
PubMed
N=0  N=0
44 articles   
Articles hand-picked  
N=1
Figure 1. Flow-chart of the systematic search.
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European studies most often included patients from tertiary
oncology departments. One randomised clinical trial from the
UK and one cross-sectional study from the USA were both
population based. The study size varied between 10 and 674
patients. Five of 13 studies included <100 patients (of which
two had <50 patients), and four studies had >250 patients. The
tumour stages varied, but most studies focused on localised
disease, and only a few focused on metastasised melanoma
(Table 3).
HRQOL measures
A total of 20 different instruments were used in the 13 studies;
seven measured HRQOL, of which ﬁve were generic
instruments, one was cancer speciﬁc and one was melanoma
speciﬁc (Tables 2 and 3). The most frequently used generic and
cancer-speciﬁc HRQOL tools were the SF-36 (5/13) and
EORTC QLQ-C30 (6/13), respectively. In three studies,
a combination of generic and cancer-speciﬁc tools was used. In
two studies, health utilities (HALex and EQ-5D) were used as
a measure of HRQOL, and in one study a melanoma-speciﬁc
(FACT-M) tool was used. Recently, the FACT-M questionnaire
was proposed as ‘a reliable and valid instrument for patients
with melanoma that can be used for the assessment of QOL in
clinical trials’ [8, 20].
In addition to HRQOL, all included studies reported on
other psychological and social constructs, such as social
support and personality structure, but these instruments were
beyond the scope of this review.
HRQOL impairment in melanoma
The results of the different studies indicated that there are three
distinct periods of HRQOL impact during the melanoma
experience: diagnosis, treatment and follow-up [19, 21]. The
immediate period following diagnosis (i.e. acute survival phase)
was often associated with high levels of HRQOL impairment
[14, 18]. Patients reported more pain, less energy and more
interference of stressors (physical and emotional) on social
activities. Importantly, patients also gave worse evaluations of
overall personal health. Acute survival is followed by extended
survival, which is dominated more by fears of recurrence and
less by the physical limitations the cancer or its associated
therapies create [21]. In the follow-up phase, psychological
distress can interfere with screening recommendations and
preventive behaviours [19].
A recent study showed that before the deﬁnite diagnosis of
melanoma, patients reported an excellent HRQOL. During the
diagnostic process, however, insomnia increased, while
emotional functioning and global health status deteriorated, as
measured by standard anxiety scales (HADS, STAI-SFF) and
the EORTC QLQ-C30 for patients ultimately diagnosed with
melanoma [14].
In a surgical randomised clinical trial (RCT) of high-risk
melanoma patients, patients with a 3 cm excision margin had
signiﬁcantly poorer mental and physical functioning (SF-36)
compared with those with a 1 cm excision margin [22]. After
3–6 months, the difference in HRQOL impact between these
two patient groups was no longer signiﬁcant, except for
a persisting poor scar perception in the 3 cm excision group.
Predictors of poor scar perception were younger age, female
gender, a 3 cm excision margin and poor physical and mental
health post-surgery. Additionally, patients with a 3 cm margin
had more complications, a longer hospital stay, more skin
grafts and greater physical impairment.
Three clinical trials assessed the effect of chemotherapeutics
and/or interferon therapy on patients’ HRQOL [9, 11, 12].
Patients who received interferon therapy scored signiﬁcantly
lower on their HRQOL in terms of functioning and symptoms
compared with the (placebo) control group. The EORTC QLQ-
C30 instrument showed that patients had signiﬁcantly worse
mean scores in role functioning (RF), emotional functioning
(EM), cognitive functioning (CF), social functioning (SF) and
global health status compared with patients in a placebo group
[11]. Although systemic drugs (e.g. interferon) decreased
patients’ HRQOL during treatment, the overall gain in HRQOL
was favourable in some patients, especially those with a poor
prognosis [12].
In one study, cognitive behavioural intervention signiﬁcantly
decreased distress (i.e. BSI and STAI scores) in patients with
medium to high baseline levels of distress [17].
predictors of HRQOL impairment
Several studies have demonstrated that overall health is the
most important predictor of melanoma’s impact on HRQOL
[8, 13, 15]. Patients with poor health are signiﬁcantly more
likely to report higher levels of HRQOL impairment or lower
levels of health utility than healthier patients. Patients who
report poor physical health have a comparable impact to those
Table 1. List of 14 criteria assessing the methodological quality of
HRQOL studies of melanoma patients
A Socio-demographic and medical data are described
(e.g. age, race, employment status, educational status,
tumour stage at diagnosis, etc.)
B Inclusion and/or exclusion criteria are formulated
C The process of data collection is described (e.g. interview
or self-report, etc.)
D The type of cancer is described.
E The results are compared between two groups or more
(e.g. health population, groups with different cancer
treatment or age, comparison with time at diagnosis, etc.).
F Mean or median and range or standard deviation of time since
diagnosis or treatment is given.
G Participation and response rates for patient groups have to be
described and have to be >75%.
H Information is presented about patient/disease characteristics of
respondents and non-respondents or if there is no selective response.
I A standardised or valid QOL questionnaire is used.
J. Results are described not only for QOL but also for the physical,
psychological and social domains.
K. Mean, median, standard deviations or percentages are reported
for the most important outcome measures.
L. An attempt is made to ﬁnd a set of determinants with the highest
prognostic value.
M.Patient signed an informed consent form before study participation.
N.The degree of selection of the patient sample is described.
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both reported the lowest HRQOL scores [8, 13]. Not only is
global health a predictor of HRQOL, it also deteriorates after
the diagnosis of melanoma due to an increase in insomnia and
pain [8, 14, 15].
In addition to health status, several psychological factors
such as non-cancer life stresses, wishful thinking and
maladaptive coping styles were important determinants of
melanoma’s level of impact on HRQOL [19]. In patients with
metastasised melanoma, low levels of social support were
signiﬁcantly associated with greater psychological distress and
poorer mental HRQOL. Additionally, low social support
decreased the likelihood of HRQOL adjustment 1 month after
treatment [16].
Table 2. HRQOL instruments used in eligible studies
Instrument Type Goals Domains/subscales
Brief Symptom Inventory (BSI) Generic Measure of emotional distress Nine clinical scales and three summary
scales. Global severity index (GSI):
sensitive measure of overall distress.
Chronic Strains Survey (CSS) Generic Measure of persistent
stressful conditions
Items concerning the existence and
perceived burden of economical and
social difﬁculties, strains in work life,
alcohol or drug abuse, other chronic
diseases, etc.
EuroQol Group (EQ-5D) Generic A ﬁve-dimensional health
state classiﬁcation
Five dimensions: mobility, self-care, usual
activities, pain/discomfort and
anxiety/depression.
Health and Activities
Limitation Index (HALex)
Generic Provides a HRQOL utility score A single numerical value for the health
state based on patients’ perceived health
status in conjunction with any activity
limitation they might experience. 0 = near
death state to 1 = perfect health with no
limitations. Previously validated against a
large population of subjects.
Short Form-36 (SF-36) Generic Assesses health functioning;
often used as a general
measure of HRQOL
Eight subscales: physical functioning, vitality,
social functioning, general health, bodily
pain, physical role, emotional role and
mental health.
Two component summary scales: physical
and mental component summary scales
(PCS and MCS).
European Organization for
Research and Treatment of
Cancer (EORTC QLQ-C30)
Cancer speciﬁc Assesses the HRQOL of cancer
patients participating in
international clinical trials
Five functional scales: physical (PF), role
(RF), cognitive (CF), emotional (EF)
and social (SF).
Three symptom scales: fatigue (FA), pain
(PA), nausea and vomiting (NV).
A global health status / QOL scale (QL).
Six single items assessing additional
symptoms commonly reported by
cancer patients: dyspnoea (DY), loss
of appetite (AP), insomnia (SL),
constipation (CO), diarrhoea (DI).
A single item on the perceived ﬁnancial
impact of the disease (FI).
Functional Assessment of Cancer
Therapy—Melanoma (FACT-M)
Melanoma
speciﬁc
Assesses the HRQOL of melanoma
patients participating in clinical trials
Fact-G items (general) questions.
Melanoma-speciﬁc sub-scale: 24 items
encompassing three HRQOL domains:
physical, emotional and social well-being.
Cassileth Scar Questionnaire Therapy
speciﬁc
Investigates patients’ opinion on the
size and cosmetic implications of
their excisions
12 items, each scored from 1 to 4 (minimum
to maximum negative cosmetic impact).
The questionnaire also contains outline
drawings of the human body on which
patients are asked to indicate the size,
shape and location of their scar [16].
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Country, year [Ref.] Research type Study population No. patients HRQOL instrument Conclusions Quality score (range 0–14)
USA, 2008 [8] Cohort prospective
12 months
MD Anderson Cancer Center:
patients recruited with new
melanoma or within the ﬁrst
3 years of follow-up.
225 FACT, EORTC QLQ,
POMS, MCSDS
Reliable QOL questionnaire
for patients with melanoma
in clinical trials.
9
aEurope, 2004 [9] Randomised
prospective
2 months
Centres throughout Europe:
patients with non-ocular
melanoma, with or without
brain metastases; phase III
study comparing fotemustine
(F) and dacarbazine (D) (one
in each of the patient arms);
metastasised disease.
229 (112F, 117D) EORTC QLQ-C30 ‘No signiﬁcant difference in
QOL between two groups.
The general tendency in the
selected QOL dimensions
was degradation over time
in both arms.’
10
Finland, 2007 [10] Cohort prospective
3–4 months after
diagnosis
Oncology Clinic of Tampere
University Hospital, Finland:
patients with cutaneous
melanoma with localised
disease. Included patients
with Clarke II, II or IV.
Breslow 0.20–7.00 mm.
Excluded patients with
in situ melanoma, Clark
V and orbital melanoma.
59 WOC, SSF, AX, LES,
CSS, RSCL, DEPS
‘Women tend to have slightly
more psychological
symptoms (P = 0.085).
Patients reported self-
perceived QOL as quite
good to good.’
8
UK, 2006 [11] Randomised
prospective
60 months
Weston Park Teaching Hospital,
Shefﬁeld: melanoma patients,
all stages.
674 EORTC QLQ-C30,
EQ5D
‘Patients in observational
group had signiﬁcantly
higher mean QOL than
interferon patients.’
8
Poland, 2005 [12] Controlled trial,
prospective
minimum of
56 days
after surgery
Department of Soft Tissue and
Bone Cancer, Institute of
Oncology, Warsaw: two equal
groups of 110 patients after
radical surgery for melanoma.
One group received supplementary
IFN-a2b therapy. Stage unclearly
mentioned.
220 EORTC QLQ-C30 ‘The IFN-a2b signiﬁcantly
affected the emotional,
social and physical health
of the patients. In spite of
adverse effects of treatment,
patients scored their
QOL as good.’
10
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Country, year [Ref.] Research type Study population No. patients HRQOL instrument Conclusions Quality score (range 0–14)
Finland, 2005 [13] Cohort prospective
3 months
after diagnosis
Oncology Clinic of Tampere
University Hospital: patients
with melanoma and breast
cancer patients.
Localised disease, newly
diagnosed.
175 (melanoma 72) WOC, SFSS, AX, LES,
RSCL, DEPS,
EORTC-QLQ
(breast cancer
module)
‘QOL of newly diagnosed
cancer patients is highly
associated with psychosocial
factors. Non-cancer life
stresses seem to be very
important in the QOL in
newly diagnosed cancer
patients. Adjuvant treatment
may compromise supportive
psychosocial factors that
enhance QOL in cancer.’
9
UK, 2006 [14] Cohort prospective
6 months
Pigmented Lesion Clinic: malignant
and non-malignant
skin lesions, all stages.
195 (melanoma 10) EORTC QLQ-C30,
HAD, STAI-SSF
‘QOL pre-diagnosis was
excellent. Emotional
functioning, insomnia
and global health status
deteriorated throughout
diagnostic process for
patients with malignant
melanoma.’
12
USA 2004 [15] Cohort prospective
9 months
Multidisciplinary Melanoma Clinic:
melanoma patients
with stages I–III.
351 MOC, BSI, SF-36,
WOC, STAI
The healthy cluster reported a
signiﬁcantly higher HRQOL
than the unhealthy clusters
when confronted with
melanoma.
11
USA 2003 [16] Cohort prospective
3 months
Anderson Cancer Centre, Houston:
population with metastatic renal
cell carcinoma or metastatic
melanoma.
Phase I/b trial for trial vaccination.
53 (melanoma 24) ISEL, IES,
BSI, SF 36
‘The results suggest that social
support buffers the negative
association between intrusive
thoughts/avoidance and
psychological adjustment.
Overall the results are
consistent with a social-
cognitive processing model
of post-trauma reactions
among cancer patients.’
10
USA, 2003 [17] Randomised
prospective
6 months
Melanoma Clinic: melanoma
patients with stages I–III
48 BSI SF-36 STAI ‘Distress signiﬁcantly reduced
after 4 CBI sessions, with
an increase in HRQOL in
patients with medium-high
distress.’
10
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9No studies have investigated the HRQOL across gender, age
and all tumour stages, except in a surgical RCT in which older
individuals were signiﬁcantly more likely to report lower levels
of physical functioning, as is expected [22]. Women reported
signiﬁcantly higher levels of anxiety than men surrounding the
diagnosis [14].
discussion
About one-third of patients with melanoma have reported
clinically signiﬁcant levels of distress, which is in accordance
with ﬁndings in other cancers. Distress was highest around the
time of diagnosis and immediately post-treatment, and
decreased over time [14, 18, 22]. Although increased levels of
HRQOL impairment are associated with poor recovery and an
increase in morbidity and maybe even disease progression [6, 8,
10, 13, 14, 17–21], relatively few studies have investigated
HRQOL in melanoma patients. The reviewed studies focused
mainly on populations from specialised (melanoma or cancer)
centres that received additional therapy during short periods of
time. The impact of melanoma on individuals from the general
population who have survived this skin cancer for many years is
not well documented.
Although the SF-36 is the most widely accepted generic
HRQOL tool, its psychometric properties have not been tested
in melanoma patients. A generic instrument allows for
comparability between melanoma patients, other diseases and
cancers, and the general population, as normative data exist for
many countries. As generic instruments may not be very
sensitive in detecting effects that are associated with speciﬁc
diseases (e.g. sun avoidance behaviour in melanoma patients
affects social functioning), the combination of a generic and
speciﬁc HRQOL instrument is most informative [23].
FACT-M, which is a melanoma-speciﬁc HRQOL
instrument that focuses on physical domains and was
designed for clinical trial settings, has recently been validated
in 273 melanoma patients and shown to be reliable, responsive
and have a good construction and convergent validity [8, 20].
Because the majority of patients diagnosed with melanoma
will most likely experience few limitations in their physical
functioning and be much more affected mentally, the content
of the FACT-M seems especially appropriate for patients with
advanced melanomas and less for those from the general
population. Fear of recurrence and changed lifestyles, due to
UV avoidance, are likely to be important HRQOL domains
that are not fully assessed in any of the available HRQOL
instruments, which indicates a lack of content validity.
Altogether, the selection of an appropriate HRQOL
instrument remains a trade-off between the psychometric
properties of the instrument, the study population and the
research objectives of the study [23].
The reported effects of systemic treatment (e.g. interferon)
on HRQOL may be inﬂuenced by the treated patient
population. Patients who agree to participate in a clinical trial
and/or receive therapy may be more motivated and optimistic,
and thus be more likely to report beneﬁt and endure more
drug-induced toxicity compared with those not receiving
systemic treatment. The latter issue is conﬁrmed by the fact that
some patients on interferon therapy, which is associated with
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treatment as good [12, 24].
In cancers that are treated with relatively non-aggressive
therapies, have relatively good survival rates and have a high
number of years lived with disability, patients’ perspectives are
very important. In addition to clinical therapy, psychological
surveillance after diagnosis and therapy may be needed,
especially among patients with poor global health status, those
with certain personality structures (e.g. maladaptive coping
styles), and those without a social network [16, 19]. Although
a pilot study indicated that a psycho-educational intervention
might improve survival in melanoma patients, a large Danish
RCT demonstrated no increased survival or recurrence-free
interval among those who were offered six weekly 2-hour
sessions of psycho-education compared with the control group
[25, 26]. In contrast, a few studies have indicated that HRQOL
impairment, psychological factors and personality structure
may affect the survival rate of melanoma patients [16, 21].
Patients with a ‘type C’ personality (i.e. tending to be
cooperative, unassertive, and repress negative emotions
through anger-avoidance) may also be less likely to survive
melanoma [16, 21].
conclusion
The proportion of patients with melanoma who report high
levels of HRQOL impairment is comparable to that observed in
other cancers. Optimal measurement of HRQOL in patients
with melanoma is challenging because of the fairly unique
characteristics of the tumour and its often straightforward
treatment. More speciﬁc HRQOL measures could assist
physicians in identifying patients who are in need of
psychological counselling, which may affect treatment, follow-
up and patients’ well-being.
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